KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and safety in tirzepatide-treated Korean adults with type 2 diabetes-A post hoc analysis of SURPASS-AP-combo and SURPASS-3.

Byung Wan Lee, Chang Beom Lee, Soo Lim, Sin Gon Kim, Nan Hee Kim, Jong Chul Won, Woo Je Lee, Min Ju Kang, Ju Young Yuh, Li Ying Du, Hyojin Lim, Kyu Jeung Ahn

Diabetes Obes Metab 27(12) 7110-7122

PMID40954943
PMCIDPMC12587258
DOI10.1111/dom.70111
发表日期2025-09-16
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other。
摘要

摘要

AIMS: This post hoc analysis assessed the efficacy and safety data in tirzepatide-treated Korean patients with type 2 diabetes (T2D). MATERIALS AND METHODS: Data specifically from Korean patients treated with tirzepatide 5, 10, or 15 mg in the multicentre, randomised, open-label, parallel-group, phase 3 trials SURPASS-AP-Combo and SURPASS-3 were extracted and analysed. Efficacy (change from baseline in glycated haemoglobin [HbA1c] and body weight, and proportions of participants achieving HbA1c and body weight targets) and safety endpoints were evaluated at week 40 (SURPASS-AP Combo) and week 52 (SURPASS-3). RESULTS: In the SURPASS-AP-Combo and SURPASS-3, 79 of 687 and 27 of 1079 tirzepatide recipients, respectively, were Korean. In Korean participants in SURPASS-AP-Combo across all tirzepatide doses, least squares mean (LSM) HbA1c was reduced from baseline by 2.75% to 3.25% and HbA1c targets of <7.0% and ≤6.5% were achieved by 84.6% to 100% at week 40; LSM body weight reductions of -6.8% to -10.9% from baseline were achieved. The composite endpoint of HbA1c ≤6.5% without body weight gain or clinically significant documented symptomatic or severe hypoglycaemia was achieved by 69.2% to 85.2% of tirzepatide recipients. Findings were similar in Korean participants of SURPASS-3. The safety profile of tirzepatide in Korean participants was generally consistent with that in the overall SURPASS-AP-Combo and SURPASS-3 populations. CONCLUSIONS: Consistent with the overall results of the SURPASS-AP-Combo and SURPASS-3 trials, this post hoc subgroup analysis found clinically meaningful reductions in HbA1c and body weight after treatment periods of 40 to 52 weeks in Koreans with T2D treated with tirzepatide.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Change in HbA1c in Korean participants and all participants: (A) change over time in SURPASS‐AP‐Combo and (B) SURPASS‐3, and change from baseline to (C) week 40 in SURPASS‐AP‐Combo and (D) week 52 in SURPASS‐3. HbA1c, glycated haemoglobin; LSM, least squares mean; SE, standard error.
非 KM Figure
FIGURE 2FIGURE 2 Percentage of Korean participants and all participants achieving therapeutic targets: (A) percentage achieving HbA1c targets at week 40 in SURPASS‐AP‐Combo and (B) at week 52 in SURPASS‐3; (C) percentage achieving body weight targets at week 40 in SURPASS‐AP‐Combo and (D) at week 52 in SURPASS‐3; and (E) percentage achieving HbA1c targets with no body weight gain or clinically significant documented symptomatic or severe hypoglycaemia at week 40 in SURPASS‐AP‐Combo. HbA1c, glycated haemoglobin.
非 KM Figure
FIGURE 3FIGURE 3 Change in body weight in Korean participants and all participants: Change over time in (A) SURPASS‐AP‐Combo; (B) SURPASS‐3, and change from baseline to (C) week 40 in SURPASS‐AP‐Combo; and (D) week 52 in SURPASS‐3. LSM, least squares mean; SE, standard error.
非 KM Figure